Stockscreener 앱 받기
0.5158
3.32%
-0.0177
시간 외 거래:
.52
0.0042
+0.81%
전일 마감가:
$0.5335
열려 있는:
$0.5289
하루 거래량:
745.41K
Relative Volume:
0.21
시가총액:
$22.93M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.77%
1개월 성능:
+8.48%
6개월 성능:
-33.53%
1년 성능:
-39.25%
1일 변동 폭
$0.5009
$0.5595
1주일 범위
$0.4831
$0.5899
52주 변동 폭
$0.2026
$4.06
Nkgen Biotech Inc Stock (NKGN) Company Profile
명칭
Nkgen Biotech Inc
전화
(949) 396-6830
주소
3001 DAIMLER ST,, SANTA ANA
NKGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.5158 | 22.93M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
NKGen Biotech Announces Administration of First Dose of - GlobeNewswire
Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan
NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq
NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan
NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register
NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire
NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com
Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Midday Stock Roundup: RxSight Down 6.1% on Weak Post-3Q Results - Orange County Business Journal
FDA fast tracks NKGen's Alzheimer's therapy troculeucel - MSN
NKGen Biotech Announces Publication of Phase 1 Troculeucel - GlobeNewswire
Market cap of NKGen Biotech Inc [NKGN] reaches 37.83M – now what? - The DBT News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
NKGen's Troculeucel Therapy Demonstrates Stability And Cognitive Improvement In AD Trial - Nasdaq
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the ... - The Bakersfield Californian
Revolutionary Alzheimer's Treatment Shows Remarkable 90% Success in Phase 1 Trial - StockTitan
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket - Benzinga India
FDA Fast Track Designation Sends Biotech Soaring Mid-Week - The Globe and Mail
FDA fast tracks NKGen's Alzheimer's therapy troculeucel By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug - TradingView
NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate - Marketscreener.com
NKGen Biotech Receives U.S. FDA Fast Track Designation for - GlobeNewswire
Revolutionary NK Cell Therapy for Alzheimer's Disease Receives FDA Fast-Track Status - StockTitan
How to Use the Immune System Against Cancer and Alzheimer's, with Dr. Paul Song - upworthyscience.com
NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy? - Defense World
Midday Stock Roundup: Alignment Healthcare Rises on Update - Orange County Business Journal
NKGen Biotech regains compliance with Nasdaq listing standards - Investing.com
NKGen Biotech secures $4.5M in convertible loan agreement - Investing.com India
NKGen Biotech secures $4.5M in convertible loan agreement By Investing.com - Investing.com Canada
NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why - Defense World
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - Asianet Newsable
NKGen Biotech Awards Stock Options to Executives - TipRanks
Head to Head Survey: HilleVax (NASDAQ:HLVX) versus NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech faces Nasdaq delisting over market value By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq delisting over market value - Investing.com
NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewswire
NKGen Biotech Secures $18M Bid for NKMax Acquisition, Expanding Global IP Rights - StockTitan
NKGen Biotech selected as preferred stalking horse bidder for NKMax - Nasdaq
NKGen Biotech faces Nasdaq compliance issue By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq compliance issue - Investing.com India
Nkgen Biotech Inc (NKGN) 재무 분석
Nkgen Biotech Inc (NKGN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):